---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-243481"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-10-25T23:59:59+00:00"
generated_at: "2026-05-30T10:10:22.659432+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene raises $60M via private placement of 6.76M shares at $8.90/share

## Summary
- Gross proceeds ~$60M from sale of 6,758,311 common shares at $8.90/share; expected close Oct 29, 2024.
- Investors include Deep Track Capital, Cormorant Asset Management, Forbion, OrbiMed, Sphera Healthcare, Vestal Point Capital, Venrock Healthcare.
- Net proceeds to fund detalimogene development, pre-commercial activities, DDX platform expansion, and working capital.
- Combined with existing cash, expected to fund operating plan into 2027.
- Leerink Partners, Piper Sandler, Guggenheim, Wells Fargo acted as placement agents.

## SEC filing metadata
- accession: 0001193125-24-243481
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312524243481/0001193125-24-243481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312524243481/d863566d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-243481
- JSON: https://secwatch.observer/filing/0001193125-24-243481.json
- Plain text: https://secwatch.observer/filing/0001193125-24-243481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.